JP2000239159A - Capsule preparation and it production - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a capsule preparation characteristic in that a medicament packed in the capsule contains at least two kinds of medicinal ingredients which are separated into a plurality of ingredient phases, and by making the separated state visibly recognizable from the outside of the capsule by a relevant person to be administered, the person an easily recognize that this capsule preparation contains a plurality of the medicinal ingredients therein and has high therapeutic efficacy, and to provide a method for producing the capsule preparation. SOLUTION: This capsule preparation is made up of a capsule and a medicament packed therein, wherein it is characterized by that the medicament is separated into a plurality of ingredient phases, the separated state is visibly recognizable from the outside of the capsule preparation, and at least one of these ingredient phases is in a liquid state.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a capsule and a method for producing the same, and more particularly, it is possible to visually confirm from the outside of the capsule that a drug filled in the capsule is separated from the capsule. The present invention relates to a capsule that can be recognized even by a user of the preparation as a capsule having high therapeutic efficacy, and a method for producing the same.

[0002]

2. Description of the Related Art Conventionally, various capsules have been sold, and among them, there is a capsule filled with a drug consisting of only a liquid component phase. In conventional capsules filled with such drugs, the capsule, which is the outer shell, is colored and opaque, so that it is often not possible to see the drugs inside, and for the user, what kind of medicinal ingredient It is difficult to imagine whether a drug comprising a liquid component phase containing is filled in a capsule.

For this reason, capsules have been developed in which the capsules are made transparent or translucent, and the medicine filled therein can be visually recognized from the outside of the capsule. However, in such capsules, even when two or more kinds of medicinal ingredients are contained as a medicine, the medicine is not filled in a separated state, but is homogeneously mixed. is there.

[0004] Therefore, when a user of the capsule observes the medicine inside the capsule from the outside, it is impossible to know how many kinds of medicinal ingredients are contained in the medicine. For this reason,
It is conceivable that the user considers that the therapeutic effect of the capsule is low and takes a combination of various drugs in addition to the capsule. However, when various drugs are taken in combination in this way, there is a risk of causing contraindications, which is rather dangerous.

[0005]

DISCLOSURE OF THE INVENTION The present invention has been made to solve the above-mentioned problems, and an object of the present invention is to provide a method in which a drug filled in a capsule contains two or more kinds of active ingredients. By separating the medicinal ingredient into a plurality of component phases and making the separated state visible from the outside of the capsule, a plurality of types of capsules are internally provided to a user of the capsule. An object of the present invention is to provide a capsule containing a medicinal ingredient, which is easy to recognize as a capsule having a high therapeutic effect, and a method for producing the same.

[0006]

According to the present invention, there is provided a capsule comprising a capsule and a drug filled in the capsule, wherein the drug is separated into a plurality of component phases. In addition, the separated state is visible from the outside of the capsule, and at least one of these component phases is in a liquid state.

[0007] As the capsule in the above-mentioned configuration, a conventionally known capsule can be used. Even a soft capsule called a soft capsule or a hard capsule called a hard capsule can be used. It does not matter. However,
When using a hard capsule, so that the drug containing the liquid component filled in the capsule does not leak out of the capsule,
It must be tightly sealed.

[0008] Further, in the drug to be filled in the capsule, it is preferable that all of a plurality of component phases constituting the drug are in a liquid state. In this case, each component phase is separated into layers. Is more preferable. The plurality of component phases include at least a component phase composed of a hydrophilic liquid and a component phase composed of a hydrophobic liquid, and it is preferable that the plurality of component phases be separated into a plurality of component phases by utilizing the difference in properties of the component phases. Together with or instead of this, the difference between the densities of the respective chemicals is set to 0.
It is also preferable to separate the drug into a plurality of component phases at 001 g / cm ³ or more.

[0009] Coloring may be performed for each component phase. For the color classification, it is preferable to use the color of the medicinal component itself, but if necessary, a colorant that does not inhibit the medicinal effect may be added to each component phase to perform the color classification. The capsule as described above is separated into a plurality of component phases, and a drug in which at least one of the component phases is in a liquid state is separated into the plurality of component phases by a capsule. It can be manufactured by filling into a capsule so that it is visible from the outside.

[0010] The capsule according to the present invention for solving the above problems is not limited to a form in which the capsule is separated into layers, and the medicine contains a hydrophilic liquid and a hydrophobic liquid. May be separated into an emulsion, and the state separated into the emulsion may be visually recognized from the outside of the capsule.

The capsule according to the present invention for solving the above problems contains a component phase in which the drug is in a liquid state and a component phase in which the drug is in a solid state. The phase and the component phase in a solid state are separated in a suspension state, and the state separated in the suspension state may be configured to be visible from the outside of the capsule. Absent.

In the above constitution, the component phase may be formed solely from the medicinal ingredient filled in the capsule, or may be formed by dissolving the medicinal ingredient in a solvent, and is not particularly limited.

[0013]

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS One embodiment of the present invention will be described below in detail. In the present embodiment, the drug filled in the capsule is separated into a plurality of component phases in the capsule, and at least one of the plurality of component phases is in a liquid state.

In the case of the component phase in a liquid state, any solvent may be used as a solvent for dissolving the active ingredient, irrespective of whether it is hydrophilic or hydrophobic as long as the solvent does not dissolve the capsule. be able to. As the hydrophilic liquid, for example, lower alcohols such as ethanol, glycerin, glyceryl triacetate, ethylene glycol, propylene glycol, polyethylene glycol,
Examples include polyhydric alcohols such as polypropylene glycol, isomerized saccharide solutions, hydrophilic liquid surfactants, and combinations thereof.

On the other hand, examples of the hydrophobic liquid include triglycerides such as medium-chain fatty acid triglycerides, corn oil,
Olive oil, safflower oil, cottonseed oil, sesame oil, soybean oil,
Rapeseed oil, peanut oil, coconut oil, sunflower oil, jojoba oil, poppy oil, liquid paraffin, lipophilic oily surfactants, and combinations thereof.

The active ingredient dissolved in the hydrophilic liquid is not particularly limited. Examples thereof include benzalkonium chloride, water-soluble vitamin, antipyrine, chlorpromazine hydrochloride, diphenhydramine hydrochloride, naphazoline hydrochloride,
Examples include guaifenesin, sodium salicylate, dextromethorphan hydrobromide, chlorpheniramine maleate, acetaminophen, caffeine, dl-methylephedrine hydrochloride, dihydrocodeine phosphate, diprofylline and the like.

On the other hand, the medicinal component dissolved in the hydrophobic liquid is not particularly limited, and examples thereof include camphor, a fat-soluble vitamin, liver oil, borneol, methenolone acetate, ibuprofen, isopropylantipyrine, ethenzamide and the like. The medicinal component may be added to each component phase, or may be added to only some component phases.

The plurality of component phases are used to make it easy to visually recognize the state in which the drug is separated into the plurality of component phases from the outside of the capsule, and to surely separate the drug into the plurality of component phases. For this purpose, it is preferable that each of them is in a liquid state. That is, it is preferable that all of the plurality of component phases are in a liquid state. In this case, it is preferable that each component phase is completely separated into layers.

As a form of separation of each component phase, there are at least two component phases in a liquid state, and these two component phases are determined by a difference in degree between a hydrophilic liquid and a hydrophobic liquid and / or a difference in liquid density. Are separated. From the viewpoint of ensuring that each component phase is separated into layers, it is more preferable not only to use the difference between hydrophilicity and hydrophobicity, but also to use the difference in the density of each component phase to separate the component phases. .

As described above, in order to separate each chemical solution in a laminated state by utilizing the difference between hydrophilicity and hydrophobicity, a hydrophilic liquid and a hydrophobic liquid can be used in an appropriate combination. Among them, from the viewpoint of separating each chemical solution in a reliably laminated state, for example, polyhydric alcohols such as glycerin, ethylene glycol, propylene glycol, polyethylene glycol, and polypropylene glycol are preferably used as the hydrophilic liquid, and the hydrophobic liquid Preferred are medium-chain fatty acid triglycerides, corn oil, soybean oil, sesame oil and the like.

On the other hand, when utilizing the difference in density, the difference between the densities of the two component phases is 0.01 g / cm ³ or more and 1 g / cm ³ or less, preferably 0.02 g / cm ³ or more and 0.5 g or less. / Cm ³ or less. That is, when the density difference is less than 0.01 g / cm ^3, each drug solution may not reliably separate in the capsule will be described later disadvantages of exceeding 1 g / cm ^3.

As an example, the density of propylene glycol used as a hydrophilic liquid is about 1.038.
g / cm ³ to about 1.042 g / cm ³ or so, the density of the medium chain fatty acid triglyceride used as the hydrophobic liquid is from about 0.94 g / cm ³ to about 0.96 g / cm ³ or so, the The difference is about 0.09 g / cm ³ .
The speed at which the drug injected into the capsule separates into each component phase can be adjusted by utilizing the difference in the density of each component phase.

Since the size of the capsule is usually about the same as that of soybeans, the use of a drug containing one kind of hydrophilic liquid and one kind of hydrophobic liquid is also required to enhance the visibility of the separated state. It is preferred to separate into two component phases, namely a two-layer state.

When the above-mentioned capsules in which the respective chemicals are separated in layers are observed from the outside, one kind of liquid in a liquid state and another liquid in a liquid state are separated vertically, and It can be seen that the lower density drug solution is separated at the upper portion inside the capsule and the lower density drug solution is separated at the lower portion inside the capsule.

In the above description, each of the drugs separated into a plurality of component phases is in a liquid state, but in the present invention, at least one of the separated plurality of component phases is in a liquid state. And the other component phases may be in a solid state. In this case, as the component phase in a solid state, a phase having a very small particle size such as a fine particle is usually used. That is, by using a hydrophilic liquid and fine particles having high hydrophobicity, or by using a hydrophobic liquid and fine particles having high hydrophilicity, the liquid is separated into fine particles, and this separated state is a capsule. It may be visible from outside the agent. Of course, in this case, the fine particles may contain a medicinal ingredient.

As described above, in the capsule according to the present invention, the state in which the drug filled therein is separated into a plurality of component phases can be visually confirmed from the outside of the capsule. The user can be informed that the capsule contains at least a plurality of types of medicinal ingredients. Therefore, those who take such capsules think that the capsules according to the present invention contain various medicinal ingredients and therefore the therapeutic efficacy of the capsules is high, and that the capsules should be taken in combination with other drugs more than necessary. No more trying. That is, by taking the capsule according to the present invention, the person taking the capsule does not have to take a method of taking a medicine that causes a contraindication.

Further, since the medicine to be filled therein is separated into a plurality of component phases, each of these component phases contains a different medicinal ingredient, and concomitant contraindications occur between these medicinal ingredients in advance. It can be adjusted so that it does not exist. That is, two or more medicinal ingredients can be safely prescribed in one capsule.

In the capsule according to the present invention, a color may be used for at least one of the plurality of separated component phases, and the plurality of separated component phases may be color-coded. At this time, the means for coloring the component phase is not particularly limited, and in addition to using a colored medicinal component forming the component phase itself, it is also possible to use a colored solvent for dissolving the medicinal component. Alternatively, a colorant may be added to the liquid component phase. When a coloring agent is used, it is preferable to dissolve the coloring agent in a very small amount of a solvent in advance and use it as a coloring liquid.

When a solid such as fine particles and a liquid are combined, the solid such as fine particles may be colored or colorless, and the solid may be colored or colorless. good. As described above, when at least one component phase of a drug separated into a plurality of component phases has a color that can be visually recognized from the outside of the capsule, the separation of the drug into the plurality of component phases is visually recognized from the outside of the capsule. It is extremely easy to perform the process, and the capsules have excellent appearance and can be obtained with good appearance.

Further, if colors are determined according to the types of medicinal components in the component phases, the compatibility of the component phases can be understood at a glance, and not only doctors and pharmacists but also those who take capsules are not limited to the contraindications. In addition, it is also possible to visually check whether or not the medicine filled in the capsule contains a component phase that does not match his constitution.

The main material forming the capsule of the capsule according to the present invention has an appropriate hardness, can make the inside of the capsule transparent or translucent so as to be visible, and can be easily formed into an arbitrary shape. Is used. The capsule is formed in a rugby ball shape by gelatin.

Glycerin is preferably added to gelatin in order to give the capsules appropriate flexibility. The shape of the capsule is not limited to a rugby ball shape, and may be a perfect sphere, and is not particularly limited.

(Production Method) Next, a method for producing the capsule according to the present invention will be described. The capsule according to the present invention contains at least a liquid, and at least one component phase of a drug having a property of being separated into a plurality of component phases upon standing can be visually recognized by a plurality of component phases formed by separation of the drug. It can be manufactured by encapsulating in a transparent or translucent capsule such that

At this time, it is preferable to color the component phases so that the components can be easily recognized. The method for encapsulating the drug in a capsule is not particularly limited, and examples thereof include a rotary method (see Japanese Patent Application Laid-Open No. 57-86351) and a seamless method.

The component phases (hydrophilic liquid, hydrophobic liquid, active ingredient, fine particles, etc.) contained in the drug are as described above, and the drug contains at least either a hydrophilic liquid or a hydrophobic liquid.

When both the hydrophilic liquid and the hydrophobic liquid are used as the component phases of the drug, when the drug is injected into the capsule, make sure that the hydrophilic liquid and the hydrophobic liquid are uniformly mixed. Therefore, it is preferable to add a surfactant to the drug to such an extent that the separation at the time of standing is not hindered. As described above, when the hydrophilic liquid and the hydrophobic liquid, which are the component phases of the drug, are uniformly mixed at the time of injection, the amounts of the hydrophilic liquid and the hydrophobic liquid to be injected into one capsule are reduced. The amount can be as close to the same as possible, and a capsule having a uniform content can be produced.

As such a surfactant, any of an anionic surfactant, a cationic surfactant, and an amphoteric surfactant may be used, as long as it is not harmful to the body, and is not particularly limited. The amount of the surfactant used is preferably 0.01% by weight or more and 100% by weight or less, and more preferably 0.02% by weight or more and 50% by weight, based on the weight of the whole drug (or the weight of the content liquid). It is more preferred that:

If the difference between the densities of the component phases in a liquid state and separated (ie, hydrophilic liquid and hydrophobic liquid) exceeds 1 g / cm ³ , even if a surfactant is used. The medicine cannot be mixed and homogenized, and the hydrophilic liquid is significantly excessively injected into the capsule as compared with the hydrophobic liquid, or the hydrophobic liquid is excessively excessively injected into the capsule as compared with the hydrophobic liquid. In some cases, the balance between the hydrophilic liquid and the hydrophobic liquid to be injected is deteriorated, and it may be difficult to prepare a capsule in which the hydrophilic liquid and the hydrophobic liquid are uniform. On the other hand, even if a surfactant is not used, a plurality of component phases may be homogenized by injecting different component phases from two or more inlets.

The capsule is manufactured by sufficiently stirring and mixing the medicine to be filled in the capsule so as to be uniform, immediately injecting into a prepared capsule, and then sealing the capsule. When the capsule is left after sealing, it is naturally separated into a plurality of component phases due to a difference in the degree of hydrophilicity / hydrophobicity, a difference in the density of the liquid, a difference in the weight between the solid and the liquid, and the like.

The time required for the drug to separate into a layer upon standing is dependent on the nature of each component phase contained in the drug, but it is usually sufficient to leave it overnight. In addition,
The time required for this separation can be appropriately adjusted by utilizing the difference in the density of the liquid, as described above.

(Emulsification) In the above description, the drug filled in the capsule is separated into a plurality of component phases, and at least one of the plurality of component phases is in a liquid state. Instead, a hydrophilic liquid and a hydrophobic liquid are contained as the component phases of the drug filled in the capsule, and the state in which the hydrophilic liquid and the hydrophobic liquid are separated in an emulsion form from the outside of the capsule. You may make it visually recognizable.

When the drug in such an emulsified state is viewed from the outside of the capsule, it can be seen that one component phase in a liquid state and another component phase in a liquid state are dispersed in particles. It is visually recognized. The emulsified state may be an oil-in-water type emulsion state in which the hydrophobic liquid becomes fine particles in the hydrophilic liquid, and the hydrophilic liquid becomes fine particles in the hydrophobic liquid. It may be emulsified water-in-oil type, but from the viewpoint of stability when separated into an emulsified state, it is preferably emulsified in an oil-in-water type emulsified state.

Note that an emulsifier may be used if necessary. Of course, in the case of this emulsion, either or both of the hydrophilic liquid and the hydrophobic liquid are colored, and the emulsion state (ie, the water-in-oil state or the oil-in-water emulsion state) is changed to the outside of the capsule. It is preferable to make it visible from the outside.

(Suspension) Instead of the above emulsion state,
A liquid component phase and a solid component phase were included as a drug to be filled in the capsule, and the liquid component phase and the solid component phase were separated into a suspension and separated. The state may be visible from outside the capsule.

In this case, as the component phase in the solid state, those having a very small particle size such as fine particles and beads are used. When the capsule containing the suspended drug is viewed from the outside, the component phase in a solid state having a small particle size such as fine particles is dispersed in one type of the component phase in a liquid state. It is visually recognized.

As the liquid component phase, a hydrophilic liquid or a hydrophobic liquid can be used. In addition, the component phase in the solid state has, for example, a very small particle size, such as fine granules, and does not dissolve in a liquid filled in the same capsule (or if dissolved, only a very small amount dissolves) ). In addition, you may use a suspending agent as needed. Of course, also in the case of this suspension, it is preferable to color one or both of the liquid component phase and the solid component phase so that the suspension state can be visually recognized from the outside of the capsule.

The method for producing a capsule in which the above-mentioned internal drug is in an emulsified or suspended state is substantially the same as the above-mentioned method for producing a capsule. In this case, since the medicine to be injected into the capsule is in an emulsion or suspended state in advance, it is not necessary to leave the capsule after the injection and sealing in the capsule.

[0048] In the above-mentioned capsules in which the drug inside the capsule is in an emulsified or suspended state,
Since the emulsified state or the suspended state can be visually recognized from the outside of the capsule, the user of the capsule can be made to recognize that the capsule contains at least a plurality of types of medicinal ingredients. Therefore, those who take such capsules think that the capsules according to the present invention contain various medicinal ingredients and therefore the therapeutic efficacy of the capsules is high, and that the capsules should be taken in combination with other drugs more than necessary. Will not be done.

Further, since the drug to be filled therein is in an emulsified or suspended state, that is, separated into a plurality of component phases, each of these component phases contains a different active ingredient, and Can be adjusted in advance so that no contraindications occur. That is,
Two or more different medicinal ingredients can be formulated in one capsule.

[0050]

EXAMPLES The present invention will be described below with reference to examples, but the following examples are used only for illustrative purposes and should not be used for limiting the technical scope of the present invention.

Example 1 1000 g of polyethylene glycol 400 (manufactured by NOF Corporation) was charged into a 5-liter glass beaker. To this glass beaker, a coloring liquid in which 0.1 g of green No. 8 dye was previously dissolved in a small amount of purified water as a coloring agent, and 10 g of lauryl dimethyl amino acid betaine were added, followed by sufficient stirring.

Then, 1000 g of medium-chain fatty acid triglyceride (trade name "Panasate P8" manufactured by NOF CORPORATION)
10 ") into the glass beaker, and then agitating the mixture in the glass beaker at about 8000 rpm for 15 minutes using a homomixer (manufactured by Tokushu Kika Kogyo Co., Ltd., HV-M) to homogenize the mixture, Was prepared.

Separately, 10 Kg (JP) of purified gelatin, 3 Kg (JP) of concentrated glycerin and 9 Kg of purified water were mixed and heated to 60 ° C. with stirring to dissolve the gelatin. Next, the bubbles in the dissolved gelatin were degassed, and then formed into a sheet.

Thereafter, two sheets of gelatin are molded into a half-capsule using a capsule molding machine, and the capsules are prepared as described above while bringing the half-capsules close to each other. 250mg of drug
Was encapsulated by a rotary die method in which 250 mg of a drug was encapsulated in a capsule composed of a soft capsule.

The resulting capsules were allowed to stand overnight to separate polyethylene glycol and medium-chain fatty acid triglyceride so as to be vertically stacked. After separation, polyethylene glycol colored green by the colorant is located in the lower layer, and it is extremely easy to see from the outside of the capsule that the encapsulated drug is separated into polyethylene glycol and medium-chain fatty acid triglyceride I was able to. For this reason, the appearance of the capsule was excellent.

(Example 2) In a 5 liter glass beaker, 1000 g of (medical rule) medium chain fatty acid triglyceride (trade name "Panasate P81" manufactured by NOF Corporation) was added.
0 "). In addition, 1
0 g of decaglyceryl heptaoleate (manufactured by Nippon Surfactant, trade name "decagulin 7-0") was charged and sufficiently stirred to disperse decaglyceryl heptaoleate.

Next, 1000 g of polyethylene glycol 400 (manufactured by NOF Corporation) containing a coloring solution obtained by dissolving 0.1 g of green No. 3 dye as a coloring agent in a small amount of purified water.
Was added to a glass beaker and stirred well. After this,
The mixture in this glass beaker is mixed at about 8000 rpm with a homomixer (HV-M type, manufactured by Tokushu Kika Co., Ltd.) at 1 rpm.
The mixture was homogenized by stirring well for 5 minutes to prepare a drug.

Next, the drug was encapsulated in a capsule made of gelatin in the same manner as in Example 1, and left standing to obtain a capsule in which 250 mg of the drug was encapsulated. As in Example 1, this capsule also has polyethylene glycol colored green by a colorant located in the lower layer, and the drug encapsulated in the capsule is separated into polyethylene glycol and medium-chain fatty acid triglyceride. Was very easily visible from the outside of the capsule. For this reason, the appearance of the capsule was excellent.

Example 3 1000 g of polyethylene glycol 400 (manufactured by NOF Corporation) was charged into a 5-liter glass beaker. To this glass beaker, a coloring solution in which 0.1 g of Blue No. 1 dye was previously dissolved in a small amount of purified water as a coloring agent, and 10 g of liquid (JP) benzalkonium chloride were added and sufficiently stirred.

Separately, 990 g of corn oil (manufactured by Honen Corporation) was added to 10 g of corn oil.
Was dissolved while heating, and 0.5 ml of mint oil was further added thereto and sufficiently stirred to disperse the mint oil. Thereafter, the mixture in the glass beaker was mixed with a homomixer (HV-M type, manufactured by Tokushu Kika Co., Ltd.) for about 800 minutes.
The mixture was homogenized by stirring well at 0 rpm for 15 minutes to prepare a drug.

Next, the drug was encapsulated in a capsule made of gelatin in the same manner as in Example 1, and then left standing to obtain a capsule in which 250 mg of the drug was encapsulated. In this capsule, it is extremely easy from the outside of the capsule that polyethylene glycol (containing benzalkonium chloride) colored blue by a colorant is located in the lower layer, and transparent corn oil (containing camphor) is located in the upper layer. Was visible.

For this reason, not only is the appearance of the capsules very excellent, but also that the capsules containing the benzalkonium chloride-containing component phase and the camphor-containing component phase are separately filled. I was able to recognize.

[0063]

As described above, in the capsule of the present invention, the state in which the medicine filled in the capsule is separated can be visually recognized from the outside of the capsule, so that the capsule can be taken. It is possible to make a person aware that this capsule contains a plurality of types of active ingredients inside, and that the therapeutic efficacy will be high. Therefore, since the user of the capsule according to the present invention does not take other drugs in combination more than necessary, it is possible to prevent the occurrence of contraindications.

Further, since the medicine to be filled therein is separated into a plurality of component phases, each of these component phases contains a different active ingredient, and concomitant contraindications occur between these active ingredients in advance. It can be adjusted so that it does not exist. That is, two or more active ingredients can be formulated in one capsule. The method for producing a capsule according to the present invention can easily produce the above-mentioned capsule.

 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Tetsuyoshi Ito 35-3, Kamiueno-cho Minamikai, Muko-shi, Kyoto Nitto Pharmaceutical Industry Co., Ltd. (72) Inventor Yasuhiko Sano 168 Hisawa, Fuji-shi, Shizuoka Tokai Capsule Co., Ltd. (72) Inventor Makoto Ito 168 Hisazawa, Fuji City, Shizuoka Prefecture Tokai Capsule Co., Ltd. (72) Inventor Emi Enomoto 168 Hisazawa, Fuji City, Shizuoka Prefecture Tokai Capsule Co., Ltd. F-term (reference) 4B048 PE10 PN04 PS01 PS11 4C076 AA55 AA56 BB01 CC01 CC31 DD38 DD46 DD51 EE23 EE42 EE53 FF43 FF70 GG01

Claims (8)

[Claims] Claims: 1. A capsule comprising a capsule and a drug filled in the capsule, wherein the drug is separated into a plurality of component phases, and the separated state is visible from outside the capsule. Wherein at least one of the component phases is in a liquid state. 2. The capsule according to claim 1, wherein each component phase is in a liquid state. 3. The capsule according to claim 1, wherein the drug is separated into layers for each component phase. 4. The capsule according to claim 1, comprising at least two types of component phases in a liquid state, and the component phases in the liquid state are separated in an emulsion form. 5. At least a component phase in a liquid state and a component phase in a solid state, wherein the component phase in the liquid state and the component phase in the solid state are suspended. The capsule according to claim 1, which is in a turbid state. 6. The method according to claim 1, further comprising a component phase composed of a hydrophilic liquid and a component phase composed of a hydrophobic liquid.
A capsule according to any one of the above. 7. The capsule according to claim 1, which is color-coded for each component. 8. A drug that is separated into a plurality of component phases and at least one of the component phases is in a liquid state is visible from outside the capsule when the drug is separated into the plurality of component phases. The method for producing a capsule according to claim 1, comprising a step of filling the capsule so as to be possible.